Key Highlights
● NervGen's audit committee determined on September 25, 2026 that financial statements for fiscal years 2025 and 2024, plus unaudited interim results for Q2 2026, should no longer be relied upon.
● The errors relate to the valuation methodology used for employee and director stock Options and for derivative Warrant liabilities carried on the balance sheet.
● NervGen stated the changes do not affect the company's cash position, cash flow, or liquidity, since both items are non-cash.
● The company plans to amend its Annual Report on Form 40-F for fiscal 2025 and its Form 6-K for Q2 2026 once the audit committee's review is complete.
NervGen Pharma Corp. (NASDAQ:NGEN) told investors on September 25, 2026 that it will restate its audited financial statements for fiscal years 2025 and 2024, along with its unaudited interim results for the second quarter of 2026, after finding non-cash valuation errors in how it accounted for employee stock options and derivative warrant liabilities. The Vancouver-based, clinical-stage biotechnology company said the mistakes overstated stock-based compensation expense and warrant liabilities, with knock-on effects to the unrealized gains and losses it had booked on warrant derivatives.
What the 6-K Discloses
NervGen's report of foreign private issuer, filed with the SEC on Form 6-K, states that the company's audit committee determined on September 25, 2026 that the previously issued financial statements for the years ended December 31, 2025 and December 31, 2024, as well as the unaudited interim financial information for the three and six months ended June 30, 2026, should no longer be relied upon. The errors relate specifically to the valuation methodology used for stock options granted to employees and directors, and for the warrant liabilities NervGen carries on its Balance Sheet as derivative instruments. Because both are non-cash items, the company says the corrections will not touch its actual cash balances.
No Impact on Cash, Still Evaluating the Math
The filing is emphatic on one point: "The above changes do not have any impact on the Company's cash position, cash flow, or liquidity," NervGen said. In other words, whatever the restated numbers eventually show, the company's bank balance and its ability to fund near-term operations are not in question.
What is still unresolved is the exact size of the correction. NervGen said it is "in the process of evaluating and finalizing the accounting conclusions and restatement adjustments," meaning the specific dollar amounts by which stock-based compensation expense, warrant liabilities, and the associated gain-or-loss line items will move have not yet been disclosed.
Amended Filings Ahead
To fix the record, NervGen said it plans to amend its annual report on Form 40-F for fiscal 2025 and its Form 6-K covering the second quarter of 2026, once the audit committee's review is complete. The company's auditors, KPMG LLP in Canada and KPMG LLP in the United States, are named in the filing, and Chief Financial Officer Keith Vendola signed the report on the company's behalf. The filing does not identify what triggered the discovery of the errors, whether internal or through the audit process, nor does it describe any changes to internal controls that may follow.
The Company's Business
NervGen Pharma is a clinical-stage biotechnology company developing therapies aimed at promoting nerve repair and regeneration, targeting conditions such as spinal cord injury and other neurological disorders. Its shares trade on the Nasdaq under the ticker NGEN. Restatements of this kind are governed by SEC and Canadian securities rules requiring a company to promptly disclose when previously filed financial statements can no longer be relied upon, which is the trigger for this 6-K.
What Comes Next for the Restated Figures
Investors should watch for whether NervGen quantifies the specific restated figures for stock-based compensation and warrant liabilities once its review concludes, and for the filing of the amended Form 40-F for fiscal 2025 and amended Form 6-K for the second quarter of 2026 once the audit committee finalizes its conclusions. Also worth tracking is any disclosure of changes to internal controls over financial reporting tied to the valuation errors, and whether the restatement affects any covenants, listing requirements, or other obligations tied to NervGen's financial statements.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...